

ABX-PF1 DIV1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Ilia L. Ouspenski
Group : 1644
Applicants : Douglas Charles Hanson et al.
Application No. : 10/612,497
Confirmation No. : 3552
Filed : July 1, 2003
For : HUMAN MONOCLONAL ANTIBODIES TO CTLA-4

New York, New York
April 21, 2005

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER BY ASSIGNEE

Abgenix, Inc. is the joint owner of 100% interest in the above-captioned application and U.S. Patent No. 6,682,736 B1, issued January 27, 2004. The undersigned, on behalf of Abgenix, Inc., hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-captioned application, which would extend beyond the expiration date of the full statutory term of U.S. Patent No. 6,682,736, including any patent term extensions, restorations or adjustments for said patent available under all applicable statutes including 35 U.S.C. §§ 154 through 156 and 173, as shortened by any terminal disclaimer filed prior to the grant of U.S. Patent No. 6,682,736 B1. The undersigned, on behalf of Abgenix, Inc., hereby agrees that any patent so granted on the

- 1 -

05/04/2005 KDOWNING 0000007 061075
01 FC:1814
130
DA

Patent Application
Attorney Docket No. ABX-PF1 DIV1
United States Patent Application No. 10/612,497

This Terminal Disclaimer is accompanied by a fee transmittal form
authorizing payment of the appropriate fee under 37 C.F.R. § 1.20(d).

Respectfully submitted,

Date: 4/21/05

Jane T. Gunnison
Jane T. Gunnison
Attorney for Applicants
c/o FISH & NEAVE IP GROUP
ROPES & GRAY LLP
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1105
Tel.: (212) 596-9000
Fax.: (212) 596-9090